Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
14°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Latest News about FDA Approval
Recent news which mentions FDA Approval
FDA Bans Vuse Menthol E-Cigs: Why Some Vapes Like Elf Bars Avoid Scrutiny, Others Don't
October 13, 2023
Tickers
BTI
MO
NFLX
Tags
FDA Approval
News
General
From
Benzinga
PharmaTher Holdings Nabs New Orphan Drug Status, Discusses Further Fast-Track, Partners For MDMA Patch
February 03, 2023
Tickers
PHRRF
RVVTF
Tags
Orphan Drug Designation
RVVTF
Markets
From
Benzinga
Bulls In A Bear Market: These 10 Stocks Clocked Gains In Excess Of 100% In 2022
December 31, 2022
Tickers
AAPL
ADMA
AMPY
ARDX
Tags
General
Oilfield Services
NEX
From
Benzinga
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
December 27, 2022
Tickers
BGNE
BIIB
CDTX
CHRS
Tags
BGNE
MDWD
Biopharma
From
Benzinga
Spectrum Gets FDA Nod For Febrile Neutropenia Candidate, Sees Commercial Launch In Q4 2022
September 09, 2022
Tickers
SPPI
Tags
Penny Stocks
Benzinga
FDA
From
Benzinga
Revance Shares Shoot Higher As FDA Cleared DAXXIFY Injection For Frown Lines
September 08, 2022
Tickers
RVNC
Tags
Biotech
Small Cap
Health Care
From
Benzinga
Sanofi's Rare Disease Drug Xenpozyme Scores FDA Approval
September 01, 2022
Tickers
SNY
Tags
FDA Approval
SNY
News
From
Benzinga
Incyte Gets FDA Nod For Hematologic Malignancies Candidate
August 26, 2022
Tickers
INCY
Tags
FDA
Benzinga
Market News
From
Benzinga
Axsome Shares Shoot Higher As FDA Approves Major Depressive Disorder Candidate
August 19, 2022
Tickers
AXSM
Tags
General
News
FDA Approval
From
Benzinga
Bluebird Secures FDA Nod For Genetic Blood Disease Candidate
August 17, 2022
Tickers
BLUE
Tags
FDA Approval
Movers & Shakers
Biotech
From
Benzinga
Arcutis Gets FDA Nod For Plaque Psoriasis Candidate, Sees Commercial Launch In Mid-August
July 29, 2022
Tickers
ARQT
Tags
ARQT
Health Care
General
From
Benzinga
Horizon Therapeutics Receives FDA Approval For Uncontrolled Gout Candidate
July 08, 2022
Tickers
HZNP
Tags
FDA Approval
HZNP
News
From
Benzinga
FDA Green Lights Ceruvia's Phase 2 Psilocybin Trial Program For Obsessive-Compulsive Disorder Treatment
June 29, 2022
Tags
FDA
Benzinga
Cannabis
From
Benzinga
Cybin's Psilocybin Analog CYB003 Gets FDA Clearance For Trial To Potentially Treat Major Depressive Disorder
June 28, 2022
Tickers
CYBN
Tags
News
FDA Approval
Legal
From
Benzinga
Rhythm Pharmaceuticals' Shares Dive Following FDA's Verdict On IMCIVREE Drug
June 16, 2022
Tickers
RYTM
Tags
General
Health Care
FDA Approval
From
Benzinga
U.S. FDA Approves Regeneron And Sanofi's Lead Drug For Skin Inflammation In Children
June 07, 2022
Tickers
REGN
SNY
Tags
REGN
Health Care
General
From
Benzinga
Major Depressive Disorder Could Soon Have Treatment Option Via Cybin's Psilocybin Analog
May 31, 2022
Tickers
CYBN
Tags
Market News
Cannabis
FDA
From
Benzinga
High Hopes For Alcohol Use Disorder Treatment: Clearmind's Successful Pre-IND Meeting With The FDA
May 26, 2022
Tickers
CMNDF
Tags
Benzinga
Market News
Cannabis
From
Benzinga
Psychedelics Biotech Companies Mark New Milestones In Drug Development Pipelines: Field Trip, Cybin and Wesana
January 11, 2022
Tickers
CYBN
FTRP
WSNAF
Tags
Regulations
FDA Approval
News
From
Benzinga
Boston Scientific's Exalt Model B Single-Use Bronchoscope Wins FDA Approval
August 11, 2021
Tickers
BSX
Tags
FDA
Benzinga
BSX
From
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.